Uric Acid and Circulatory Diseases: From Biomarker to Potential Cardiovascular Risk Factor
Main Article Content
Abstract
Background: Hyperuricemia has traditionally been regarded as a biochemical marker of gout and urate crystal deposition diseases. In recent years, increasing experimental and epidemiological evidence has suggested a broader role for serum uric acid (SUA) in the development and progression of cardiovascular and circulatory disorders.
Objective: To review the current evidence linking hyperuricemia with vascular disease and to discuss the potential pathophysiological mechanisms underlying its association with cardiovascular morbidity and mortality.
Methods: A narrative review of experimental, epidemiological, and clinical studies evaluating the relationship between serum uric acid and major circulatory diseases, including hypertension, coronary artery disease, heart failure, cerebrovascular disease, and peripheral arterial disease.
Results: Elevated SUA levels are associated with endothelial dysfunction, oxidative stress, chronic inflammation, vascular smooth muscle proliferation, and activation of the renin-angiotensin-aldosterone system. These mechanisms contribute to vascular remodeling and atherosclerosis. Numerous observational studies have demonstrated independent associations between hyperuricemia and arterial hypertension, coronary artery disease, heart failure, stroke, peripheral arterial disease, and cardiovascular mortality. Furthermore, hyperuricemia frequently coexists with chronic kidney disease, diabetes mellitus, obesity, and metabolic syndrome, supporting its role within the emerging cardio-renal-metabolic continuum.
Conclusions: Hyperuricemia is increasingly recognized as a potentially modifiable cardiovascular risk factor rather than merely a marker of comorbidity. Although definitive evidence of causality remains incomplete, current data support a significant contribution of uric acid to vascular damage and circulatory disease progression. Future randomized clinical trials are needed to establish whether urate-lowering therapies can improve cardiovascular outcomes beyond their established role in gout management.
Downloads
Article Details
Copyright (c) 2026 Duranti E, et al.

This work is licensed under a Creative Commons Attribution 4.0 International License.
Yu W, Cheng JD. Uric acid and cardiovascular disease: an update from molecular mechanism to clinical perspective. Front Pharmacol. 2020;11:582680. Available from: https://doi.org/10.3389/fphar.2020.582680 DOI: https://doi.org/10.3389/fphar.2020.582680
Saito Y, Tanaka A, Node K, Kobayashi Y. Uric acid and cardiovascular disease: a clinical review. J Cardiol. 2021;78(1):51-57. Available from: https://doi.org/10.1016/j.jjcc.2020.12.013 DOI: https://doi.org/10.1016/j.jjcc.2020.12.013
Ndrepepa G. Uric acid and cardiovascular disease: recent evidence on the association and underlying mechanisms. J Lab Precis Med. 2025;10:18. Available from: https://jlpm.amegroups.org/article/view/10145/html DOI: https://doi.org/10.21037/jlpm-25-8
Ciarambino T, Crispino P, Giordano M. Hyperuricemia and endothelial function: is it a simple association or do gender differences play a role in this binomial? Biomedicines. 2022;10(12):3067. Available from: https://doi.org/10.3390/biomedicines10123067 DOI: https://doi.org/10.3390/biomedicines10123067
Borghi C, Agabiti Rosei E, Bardin T, et al. Elevated uric acid as a cardiovascular risk factor. Eur Soc Cardiol Cardiol Pract. 2021.
Wang JJ, Yi JK, Zhou LR, Chen J, Zhang BQ, Huang HM, et al. A systematic review of the connection between serum uric acid levels and the risk of cardiovascular disease. Front Cardiovasc Med. 2025;12:1577952. Available from: https://doi.org/10.3389/fcvm.2025.1577952 DOI: https://doi.org/10.3389/fcvm.2025.1577952
Kuwabara M, Hisatome I, Ae R, et al. Hyperuricemia, a new cardiovascular risk. Nutr Metab Cardiovasc Dis. 2025;35(3):103796. Available from: https://doi.org/10.1016/j.numecd.2024.103796 DOI: https://doi.org/10.1016/j.numecd.2024.103796
Du L, Zong Y, Li H, Wang Q, Xie L, Yang B, et al. Hyperuricemia and its related diseases: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024;9:212. Available from: https://doi.org/10.1038/s41392-024-01916-y DOI: https://doi.org/10.1038/s41392-024-01916-y
Muiesan ML, Agabiti Rosei C, Paini A, et al. Serum uric acid and left ventricular mass index independently predict cardiovascular mortality: the URRAH Project. Eur J Intern Med. 2023;114:58-65. Available from: https://doi.org/10.1016/j.ejim.2023.04.010 DOI: https://doi.org/10.1016/j.ejim.2023.04.010
Jiang H, Su Y, Liu R, Xu X, Xu Q, Yang J, Lin Y. Hyperuricemia and the risk of stroke incidence and mortality: a systematic review and meta-analysis. Arch Rheumatol. 2025;40(1):128-143. Available from: https://doi.org/10.46497/archrheumatol.2025.10808 DOI: https://doi.org/10.46497/ArchRheumatol.2025.10808